Ocuphire Pharma, Inc. OCUP
We take great care to ensure that the data presented and summarized in this overview for Ocuphire Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OCUP
View all-
Vanguard Group Inc Valley Forge, PA992KShares$1.05 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$288,6170.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX166KShares$175,6960.0% of portfolio
-
Richmond Brothers, Inc. Jackson, MI156KShares$164,9570.13% of portfolio
-
Black Rock Inc. New York, NY107KShares$113,3510.0% of portfolio
-
Knoll Capital Management, LLC Miami, FL100KShares$106,0000.06% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il86.8KShares$92,0280.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny70.6KShares$74,8450.0% of portfolio
-
State Street Corp Boston, MA70.5KShares$74,7010.0% of portfolio
-
Morgan Stanley New York, NY56.1KShares$59,4610.0% of portfolio
Latest Institutional Activity in OCUP
Top Purchases
Top Sells
About OCUP
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Insider Transactions at OCUP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2024
|
George Magrath Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,706
+1.93%
|
$9,706
$1.02 P/Share
|
|
Nov 15
2024
|
George Magrath Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
90,294
+15.74%
|
$90,294
$1.01 P/Share
|
|
Nov 07
2024
|
Benjamin R Yerxa President |
BUY
Grant, award, or other acquisition
|
Direct |
332,800
+50.0%
|
-
|
|
Nov 01
2024
|
George Magrath Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,050
-8.62%
|
$37,050
$1.18 P/Share
|
|
Oct 22
2024
|
Jean Bennett |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Jun 11
2024
|
Jay Pepose |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+18.57%
|
-
|
|
Jun 11
2024
|
Richard J Rodgers |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+14.68%
|
-
|
|
Jun 11
2024
|
Susan Benton |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+22.71%
|
-
|
|
Jun 11
2024
|
Cam Gallagher |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+34.81%
|
-
|
|
Jun 11
2024
|
James S J Manuso |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+23.76%
|
-
|
|
Jun 11
2024
|
Sean Ainsworth |
BUY
Grant, award, or other acquisition
|
Direct |
41,143
+31.77%
|
-
|
|
May 22
2024
|
Ashwath Jayagopal Chief Scientific & Dev. Ofc. |
BUY
Open market or private purchase
|
Direct |
3,500
+4.27%
|
$3,500
$1.76 P/Share
|
|
May 17
2024
|
George Magrath Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+1.15%
|
$5,000
$1.75 P/Share
|
|
Apr 11
2024
|
Jay Pepose |
BUY
Grant, award, or other acquisition
|
Direct |
32,000
+18.68%
|
-
|
|
Mar 21
2024
|
Joseph K Schachle Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$4,000
$2.05 P/Share
|
|
Mar 21
2024
|
Nirav S. Jhaveri Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+6.25%
|
$20,000
$2.1 P/Share
|
|
Mar 18
2024
|
George Magrath Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+5.56%
|
$25,000
$1.96 P/Share
|
|
Feb 12
2024
|
Ashwath Jayagopal Chief Scientific & Dev. Ofc. |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+50.0%
|
-
|
|
Feb 12
2024
|
Nirav S. Jhaveri Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
140,000
+50.0%
|
-
|
|
Jan 18
2024
|
Rabourn Amy Zaremba SVP of Finance |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+32.61%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.12M shares |
|---|---|
| Open market or private purchase | 146K shares |
| Payment of exercise price or tax liability | 46.3K shares |
|---|